Literature DB >> 16490172

Knockdown of Stat3 expression using RNAi inhibits growth of laryngeal tumors in vivo.

Li-fang Gao1, Lian-ji Wen, Hao Yu, Ling Zhang, Yan Meng, Yue-ting Shao, De-qi Xu, Xue-jian Zhao.   

Abstract

AIM: To study the effect of pSilencer1.0-U6-siRNA-stat3 on the growth of human laryngeal tumors in nude mice.
METHODS: Hep2 cells were transplanted into nude mice, then at the time of tumor formation, growth rates were observed. After the tumor formed, pSilencer1.0-U6-siRNA-stat3 was injected. Tumor volumes were calculated, and growth curves were plotted. Representative histological sections were taken from mice bearing transplantation tumors in both treated and control groups, and stat3, pTyr-stat3, Bcl-2, cyclin D1, and survivin expression were detected by Western blotting. survivin mRNA levels were detected by Northern blotting, hematoxylin and eosin staining and terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end-labeling (TUNEL) assay to confirm the apoptosis of tumors.
RESULTS: In nude mice, pSilencer1.0-U6-siRNA-stat3 significantly suppressed the growth of tumors compared with controls (P<0.01). It suppressed stat3 expression, and downregulated BcL2, cyclin D1, and survivin expression within the tumor. This significantly induced apoptosis of the tumors.
CONCLUSION: pSilencer1.0-U6-siRNA-stat3 was able to inhibit the growth of transplanted human laryngeal tumors in nude mice and induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490172     DOI: 10.1111/j.1745-7254.2006.00277.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  12 in total

1.  Small interfering RNA survivin and GRIM-19 co-expression salmonella plasmid inhibited the growth of laryngeal cancer cells in vitro and in vivo.

Authors:  Lian-Ji Wen; Li-Fang Gao; Chun-Shun Jin; He-Jia Zhang; Kun Ji; Jing-Pu Yang; Xue-Jian Zhao; Ming-Ji Wen; Guo-Fang Guan
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

2.  Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.

Authors:  Yuelong Ma; Claudia M Kowolik; Piotr M Swiderski; Marcin Kortylewski; Hua Yu; David A Horne; Richard Jove; Otavia L Caballero; Andrew J G Simpson; Fook-Thean Lee; Vinochani Pillay; Andrew M Scott
Journal:  ACS Chem Biol       Date:  2011-07-26       Impact factor: 5.100

3.  Downregulation of STAT3 signaling induces apoptosis but also promotes anti-apoptotic gene expression in human pancreatic cancer cell lines.

Authors:  Wolfgang Glienke; Eva Hausmann; Lothar Bergmann
Journal:  Tumour Biol       Date:  2010-12-21

4.  Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation.

Authors:  Dong-bo Liu; Guang-yuan Hu; Guo-xian Long; Hong Qiu; Qi Mei; Guo-qing Hu
Journal:  Acta Pharmacol Sin       Date:  2012-04-16       Impact factor: 6.150

5.  Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma.

Authors:  Mark A Scheper; Nikolaos G Nikitakis; Risa Chaisuparat; Silvia Montaner; John J Sauk
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

6.  STAT3 silencing with lentivirus inhibits growth and induces apoptosis and differentiation of U251 cells.

Authors:  Guang-hui Li; Hong Wei; Zheng-tang Chen; Sheng-qing Lv; Chang-lin Yin; Dong-lin Wang
Journal:  J Neurooncol       Date:  2008-10-07       Impact factor: 4.130

7.  Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma.

Authors:  Tingyan Liu; Meixia Zhang; Hongliang Zhang; Chunyan Sun; Yihui Deng
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-02-29       Impact factor: 2.503

Review 8.  Nucleic acid-based approaches to STAT inhibition.

Authors:  Malabika Sen; Jennifer R Grandis
Journal:  JAKSTAT       Date:  2012-10-01

Review 9.  Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit.

Authors:  Daniel E Johnson
Journal:  Chin J Cancer       Date:  2012-01-17

10.  SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer.

Authors:  Z Zhou; M Wang; J Li; M Xiao; Y E Chin; J Cheng; E T H Yeh; J Yang; J Yi
Journal:  Oncogene       Date:  2016-05-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.